Traditional Chinese medicine composition for loosening bowel to relieve constipation and application of traditional Chinese medicine composition in preparation of food, health food and medicine
Through the combination of traditional Chinese medicine compositions such as Polygonatum, Angelica sinensis, and Cistanche, the adverse reactions and drug dependence of existing constipation treatment drugs were solved, significantly improved constipation symptoms, increased fecal particle count and water content, improved intestinal motility, and achieved moisturizing The effect of intestinal laxatives.
Patent Information
- Application Number
- CN202410988335.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-12
AI Technical Summary
The existing constipation treatment drugs have adverse reactions such as abdominal distension and urgent bowel movements, and long-term use can easily lead to drug dependence and damage to liver and kidney function. Most Chinese medicine laxative products are used to treat severe medication, which may lead to body fluid exhaustion and more serious constipation.
Using traditional Chinese medicine compositions such as Polygonatum, Angelica sinensis, Cistanche, Hemp Seed, Buddha's hand, peach kernel, Platycodon, bitter almond, etc., to improve constipation symptoms by invigorating qi and nourishing yin, healing blood, helping yang, strengthening the spleen and moistening the lungs, it can improve constipation symptoms and prepare it into traditional Chinese medicine. The composition is used in food, health food and medicine.
Significantly improve the symptoms of constipation, increase the number of feces and water content, reduce the time of the first black stool, improve intestinal motility, reduce gastrin levels, increase the content of beneficial intestinal peptides in serum, and reduce the constipation manifestations of constipation model mice.
Smart Images

Figure CN118924842A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of health food, and relates to a Chinese medicine composition for moistening intestines and relieving constipation and application thereof in preparing food, health food and medicine. Background Art
[0002] Constipation is a common digestive system symptom with reduced bowel movements, difficult defecation, and abnormal stool quality as the main clinical manifestations. It can be divided into functional constipation and organic constipation. Chronic constipation is defined as constipation that lasts for ≥ 6 months. Functional constipation is a type of constipation without organic lesions, structural abnormalities, or metabolic disorders, excluding irritable bowel syndrome, and falls within the category of "constipation" in traditional Chinese medicine.
[0003] The symptom of constipation was first seen in Huangdi Neijing, where it was called "difficult defecation" and "unfavorable bowel movements". Zhang Zhongjing's Treatise on Febrile and Miscellaneous Diseases called it "spleen restriction". Traditional Chinese medicine believes that the causes of constipation include congenital deficiency, improper diet, emotional disorders, long-term sitting and little movement, fatigue, physical weakness after illness and childbirth, and drugs. The basic pathogenesis is dysfunction of the large intestine. Although the disease is located in the large intestine, it is closely related to the dysfunction of the spleen, stomach, lungs, liver, and kidneys. In particular, the lungs and large intestine are exterior and interior. At the same time, the stomach's descent is a necessary condition for the lungs to descend. If the ascending and descending of the lung qi is disordered, the dregs cannot be discharged along the mechanism of the stomach qi descending turbidity, and constipation occurs. TCM treatment of constipation is mainly based on defecation. The seven syndrome types of heat accumulation constipation, cold accumulation constipation, qi stagnation constipation, qi deficiency constipation, blood deficiency constipation, yin deficiency constipation, and yang deficiency constipation are treated according to the principles of syndrome differentiation and treatment: clearing heat and moistening the intestines, warming and dispersing accumulation, smoothing qi and removing stagnation, replenishing qi and moistening the intestines, nourishing yin and moistening dryness, and warming and moistening the bowels. It can be seen that deficiency constipation accounts for the majority of constipation syndrome types. At present, western medicine mainly uses osmotic laxatives, stimulant laxatives, stool softeners, fiber supplements, 5-hydroxytryptamine 4 (5-HT4) receptor agonists, colon secretagogues, etc., but there are adverse reactions such as abdominal distension and urgent defecation, and discontinuation is easy to recur. Long-term use of cathartic drugs is prone to drug dependence, and even abdominal distension, abdominal cramps, liver and kidney damage and colon melanosis, etc., which can cause cancer in severe cases; most Chinese herbal laxative products use strong drugs such as rhubarb to varying degrees, but Zhu Danxi in the Jin and Yuan Dynasties believed that strong drugs were forbidden to be used for constipation, and proposed that "if strong drugs are used to expel it, the body fluids will be lost, the qi and blood will be consumed, and although it is temporarily unblocked, it will become constipated." For this reason, a Chinese herbal composition for moistening the intestines and laxatives and a preparation method thereof are proposed, which are suitable for constipation due to deficiency. Summary of the invention
[0004] The present invention provides a Chinese medicine composition for moistening the intestine and relieving constipation:
[0005] The invention provides a Chinese medicine composition for moistening intestines and facilitating bowel movements. The composition comprises the following raw materials in parts by weight: 9-15 parts of polygonatum, 6-12 parts of angelica, 6-10 parts of cistanche, 5-14 parts of hemp seeds, 3-14 parts of citron, 5-10 parts of peach kernel, 6-10 parts of platycodon and 5-10 parts of bitter almond.
[0006] The preferred solution is 10 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seeds, 10 parts of bergamot, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0007] As an improvement of the present invention, the polygonatum is preferably polygonatum sibiricum with wine.
[0008] As another improvement of the present invention, the obtained product is prepared by the following preparation method: polygonatum, angelica, cistanche, hemp seed, bergamot, peach kernel, platycodon, and bitter almond are crushed into coarse powder, an appropriate amount of honey powder is added, and the powder is filled into a non-woven bag.
[0009] As another improvement of the present invention, the obtained product is prepared by the following preparation method: step (1): taking polygonatum, angelica, cistanche, hemp seed, citron, peach kernel, platycodon, and bitter almond, adding water to extract 3 times, adding 8 times, 8 times, and 6 times the weight of the decoction pieces of water respectively, decocting for 40 minutes each time, filtering to obtain a decoction, combining and setting aside; step (2): decompressing and concentrating the decoction obtained in step (1), vacuum drying, and obtaining a dry extract, which is the solid Chinese medicine composition.
[0010] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in the preparation of food, health food and medicine with the function of moistening intestines and relieving constipation.
[0011] The composition characteristics of each raw material in the present invention are introduced as follows: Traditional Chinese medicine believes that the causes of constipation include insufficient congenital endowment, uncontrolled diet, emotional disorder, long-term sitting and less movement, fatigue and physical weakness, post-illness and postpartum, and drug-induced, and the basic pathogenesis is the failure of large intestine conduction. "Suwen Linglan Secret Classic" says: "The large intestine is the official of conduction, and changes come out of it." Intestinal lubrication is the prerequisite for the large intestine to play the main function of fluid and transfer dregs, and the failure of large intestine conduction is an important factor leading to constipation. "Zhubingyuanhou Lun Daxiaoyi" says: "The difficulty of defecation is caused by the imbalance of the five internal organs, the partial deficiency and excess of yin and yang, and the disharmony of the three burners, so the cold and heat are combined." Although the disease is in the large intestine, it is closely related to the dysfunction of the spleen, stomach, lungs, liver, kidneys and other internal organs. Traditional Chinese medicine is mainly oriented to functional constipation. Clinically, it is usually aimed at seven syndrome types of heat accumulation constipation, cold accumulation constipation, qi stagnation constipation, qi deficiency constipation, blood deficiency constipation, yin deficiency constipation, and yang deficiency constipation, and the principle of syndrome differentiation and treatment is adopted for treatment. It can be seen that deficiency constipation accounts for most of the constipation symptom types. Since constipation patients use bitter and cold laxatives for a long time, it is easy to cause spleen and stomach damage, resulting in loss of qi and blood biochemical source, and finally qi, yin, and blood deficiency. "Deficiency" is mainly manifested as weakness of the middle jiao and spleen and stomach. Most patients are accompanied by symptoms such as pale red tongue, thin white tongue coating, and weak pulse. "Spleen and Stomach Theory" says: "The large intestine is responsible for body fluid... receiving the nourishing qi of the stomach, it can move body fluid to the upper jiao, irrigate the skin, and enrich the pores." Spleen and stomach damage, spleen and stomach water and grain function disorder, thin granary and lack of source, resulting in intestinal loss of moisture or inability to push the dregs downward, or due to stagnation of pathological products such as phlegm and dampness, the dregs are accumulated, resulting in constipation. The lungs and large intestine are exterior and interior, and lung qi deficiency will cause the large intestine to be unable to move normally. At the same time, the stomach's descent is a necessary condition for the lung's descending. If the lung qi is disordered, the dregs cannot be discharged along the mechanism of the stomach qi descending turbidity, resulting in constipation. Blood deficiency and body fluid deficiency, yin fluid damage or deficiency, poor distribution and no water boat, yin deficiency and dry intestines, constipation. Kidney is the innate foundation of the human body, which contains true yin and true yang, and has an important influence on defecation and urine. The conduction and excretion of stool are inseparable from the driving effect of yang qi; at the same time, the yang qi of the large intestine mainly comes from kidney yang. When kidney yang is sufficient, the intestinal qi is unobstructed, the conduction is strong, and the stool can be excreted normally. Once kidney yang is insufficient, the intestinal qi is blocked, and the waste in the body is slowly conducted, resulting in dry stool, and finally constipation. In the Jin and Yuan Dynasties, Zhu Danxi, based on the theory of dryness and blood deficiency, believed that strong drugs were forbidden for constipation, and proposed that "if you use strong drugs to expel it, the body fluid will be lost, the qi and blood will be consumed, and although it is temporarily unobstructed, it will be constipated immediately"; Li Dongyuan, based on the theory of yin fire injuring body fluid, emphasized the method of invigorating qi, moistening dryness and harmonizing blood in treatment.
[0012] According to the above analysis, the present invention improves constipation through the following aspects: one is to invigorate qi and nourish yin, qi deficiency, then the intestinal tract pushes the power insufficient; yin deficiency, body fluid deficiency, then no water boat stops; the second is to harmonize blood, blood deficiency and body fluid deficiency then dry intestine constipation; the third is to assist yang, kidney yang is sufficient, intestinal viscera qi is unobstructed, conduction is powerful, and defecation is normal; the fourth is to invigorate the spleen and moisten the lungs, the spleen and stomach are the acquired foundation, the source of qi and blood biochemistry; the lungs and large intestine are exterior and interior, the upper jiao lung qi is opened and discharged, and the lower orifices are self-opening. The raw materials of the present invention all belong to the category of "medicine and food are of the same origin", and have medicinal functions at the same time, Cistanche deserticola invigorates kidney yang, invigorates essence and blood, moisturizes the intestines and relieves constipation, and is the monarch drug; Polygonatum sibiricum invigorates qi and nourishes yin, invigorates the spleen, moisturizes the lungs, and invigorates the kidneys, Angelica sinensis invigorates blood and promotes blood circulation, moisturizes the intestines and relieves constipation, and Fructus hemp moisturizes the intestines and relieves constipation, and is the minister drug. Buddha's hand can soothe the liver and regulate qi, dry dampness and resolve phlegm, peach kernel can invigorate blood circulation and remove blood stasis, moisten the intestines and relieve constipation, bitter almond can lower qi and relieve asthma, moisten the intestines and relieve constipation, and they are all adjuvant drugs. Platycodon grandiflorum can clear the lungs and remove phlegm, and it is the boat of all drugs and the guiding drug. The compatibility of all drugs is mutually beneficial and is suitable for constipation due to deficiency syndrome.
[0013] The medicinal properties, efficacy and specific results of modern pharmacological research of each raw material in the present invention are introduced as follows:
[0014] Cistanche deserticola is the dried fleshy stem with scale leaves of Cistanche deserticola Y.C.Ma, a plant of the Orobanchaceae family. It is dug up in spring when the seedlings just emerge from the soil or before the ground freezes in autumn, and the stem tip is removed. Cut into sections and sun-dried. It is sweet, salty, and warm. It enters the kidney and large intestine meridians. It replenishes kidney yang, benefits essence and blood, and moistens the intestines and promotes bowel movements. It is used for kidney yang deficiency, essence and blood deficiency, impotence and infertility, soreness of the waist and knees, weakness of the tendons and bones, and constipation caused by dry intestines. The main active ingredients of Cistanche deserticola are phenylethanoid glycosides (PeGs), cyclopentane ether terpenes, lignin, polysaccharides and other chemical components. It also contains monostearate, organic acids, nucleosides, nitrogen-containing organic matter and inorganic trace elements. Cistanche deserticola has kidney regulating effects, liver protection effects, gastrointestinal regulation effects, and cell proliferation inhibition effects.
[0015] Hemp seed is the dried mature fruit of Cannabis sativa L., a plant of the Moraceae family. The fruit is harvested in autumn when it is ripe, and then the impurities are removed and dried in the sun. It is sweet and neutral. It enters the spleen, stomach and large intestine meridians. It moisturizes the intestines and promotes bowel movements. It is used for blood deficiency, body fluid deficiency, dry intestines and constipation. Hemp seed contains rich nutrients and natural active ingredients, including 20% to 25% protein, 20% to 30% carbohydrates, 10% to 15% fiber and rich minerals. It has the functions of adjusting the intestinal environment, improving the composition of intestinal flora and protecting the intestinal mucosa.
[0016] Polygonatum sibiricum is the dried rhizome of Polygonatum kingianum Coll.et Hemsl., Polygonatum sibiricum Red. or Polygonatum cyrtonema Hua, all of the Liliaceae family. According to different shapes, it is commonly known as "big polygonatum", "chicken-headed polygonatum" and "ginger-shaped polygonatum". It is collected in spring and autumn, the fibrous roots are removed, washed, and slightly scalded in boiling water or steamed until thoroughly cooked, and dried. It is sweet and neutral. It enters the spleen, lung and kidney meridians. It replenishes qi and nourishes yin, strengthens the spleen, moistens the lungs and benefits the kidneys. It is used for spleen and stomach qi deficiency, fatigue, insufficient stomach yin, dry mouth and poor appetite, dry cough due to lung deficiency, hemoptysis due to overwork, insufficient essence and blood, soreness of waist and knees, premature graying of hair and beard, and internal heat and thirst. In the "Famous Doctors' Records", Polygonatum sibiricum is recorded as "taking it for a long time will make you lighter and prolong your life without hunger", and it is a traditional tonic medicine for both medicine and food. Traditional Chinese medicine theory believes that the processing of Polygonatum sibiricum can increase its efficacy and reduce its side effects, so wine Polygonatum sibiricum is often used. Quercetin in Polygonatum sibiricum is a natural flavonoid antioxidant that can improve constipation symptoms by regulating intestinal neurotransmitters and gastrointestinal hormones and affecting intestinal flora. Low doses of Polygonatum sibiricum neutral polysaccharide PSP-NP-I can improve pathological changes in jejunum, ileum, colon and lung tissue groups, and have a significant inhibitory effect on the gene expression of pro-inflammatory factors, including IL-12A, IL-12B, IL-23, IL-17, IL-6, IL-lβ and TNF-a.
[0017] Angelica sinensis is the dried root of Angelica sinensis (Oliv.) Diels, a plant of the Umbelliferae family. Angelica sinensis is a perennial herb, 0.4-1 meters high. The root is cylindrical, branched, with many fleshy fibrous roots, yellow-brown, and has a strong aroma. The stem is upright, green-white or purple, with deep grooves, smooth and hairless. The roots are dug in late autumn, the fibrous roots and mud are removed, and after the water evaporates slightly, they are tied into small bundles, put on the shed, and slowly smoked dry with fireworks. It is sweet, pungent, and warm. It enters the liver, heart, and spleen meridians. It replenishes blood and promotes blood circulation, regulates menstruation and relieves pain, and moistens the intestines and promotes bowel movements. It is used for blood deficiency and sallow complexion, dizziness and palpitations, irregular menstruation, amenorrhea and dysmenorrhea, asthenic abdominal pain, rheumatic arthralgia, injuries from falls, carbuncles, sores, and constipation due to dry intestines. Wine-boiled Angelica sinensis promotes blood circulation and promotes menstruation. It is used for amenorrhea and dysmenorrhea, rheumatic arthralgia, and injuries from falls. Angelica sinensis is a "holy medicine for gynecology" because of its efficacy. It is mainly produced in southeastern Gansu, with Minxian producing the most and of the best quality, followed by Yunnan, Sichuan, Shaanxi, Hubei and other provinces, all of which are cultivated. Angelica sinensis can improve the symptoms of constipation and blood deficiency in model rats to varying degrees, and enhance gastrointestinal propulsion function. Its laxative mechanism is related to lubricating the intestine, promoting intestinal water and mucus secretion, increasing the volume of intestinal contents, enhancing intestinal motility, and regulating gastrointestinal hormones, neurotransmitters and interstitial cells of Cajal.
[0018] Buddha's hand is the dried fruit of Citrus medica L.var.sarcodactylis Swingle, a plant of the Rutaceae family. The fruit is harvested in autumn before or when it turns yellow, cut into thin slices, and dried in the sun or at low temperature. It tastes pungent, bitter, sour, and warm. It enters the liver, spleen, stomach, and lung meridians. It soothes the liver and regulates qi, harmonizes the stomach and relieves pain, and dries dampness and resolves phlegm. It is used for liver and stomach qi stagnation, chest and flank pain, fullness in the stomach, loss of appetite and vomiting, and coughing with phlegm. Buddha's hand has a good regulating effect on the gastrointestinal tract and can promote gastrointestinal motility. The naringin in it can significantly increase the 24-hour stool volume, fecal moisture, and intestinal transit rate of constipated mice, increase the thickness of mucosal and muscle tissues, and regulate neurotransmitters in the colon.
[0019] Peach kernel is the dried mature seed of Prunus persica (L.) Batsch or Prunus davidiana (Carr.) Franch. of the Rosaceae family. The fruit is harvested after maturity, the pulp and shell are removed, the seeds are taken out and dried in the sun. It tastes bitter, sweet and neutral. It enters the heart, liver and large intestine meridians. It can promote blood circulation and remove blood stasis, moisten the intestines and relieve constipation, and relieve cough and asthma. It is used for amenorrhea, dysmenorrhea, abdominal masses, lung abscesses and intestinal abscesses, injuries from falls, dry intestines and constipation, cough and asthma. The main components of peach kernel are fatty oils, glycosides, proteins and amino acids, volatile oils, steroids and their glycosides, etc. The fatty oil contained in it has a good effect on promoting gastrointestinal motility. The inhibitory strength of peach kernel water extract, amygdalin and peach kernel fatty oil on platelet aggregation decreases in descending order. Peach kernel alcohol extract can also inhibit platelet aggregation, and its petroleum ether part and the palmitic acid and oleic acid separated from it can significantly prolong the thrombin time, thereby exerting the effect of promoting blood circulation and removing blood stasis.
[0020] Platycodon grandiflorum is the dried root of Platycodon grandiflorum (Jacq.) A.DC. of the Campanulaceae family. It is collected in spring and autumn, washed, the fibrous roots are removed, the outer skin is peeled while fresh or not, and dried. It is bitter, pungent, and neutral. It enters the lung meridian. It clears the lungs, relieves sore throat, removes phlegm, and discharges pus. It is used for cough with phlegm, chest tightness, sore throat, hoarseness, and pulmonary abscess with vomiting pus. Modern chemical composition and pharmacological research has found that Platycodon grandiflorum phytochemical research has found more than 100 compounds, including triterpenoid saponins, flavonoids, phenolic acids, phytosterols, and polysaccharides, among which triterpenoid saponins are the main active ingredients, which have anti-cough, antioxidant, anti-tumor, anti-diabetic, anti-inflammatory, anti-obesity, immunomodulatory, cardiovascular protection, and liver protection effects.
[0021] Bitter almonds are the dried mature seeds of Prunus armeniaca L.var.ansu Maxim., Prunus sibirica L., Prunus mandshurica (Maxim.) Koehne or Prunus armeniaca L. of the Rosaceae family. The mature fruits are harvested in summer, the pulp and shell are removed, the seeds are taken out and dried in the sun. Bitter, slightly warm; slightly toxic. It enters the lung and large intestine meridians. It can reduce qi, relieve cough and asthma, and moisten the intestines and promote bowel movements. It is used for cough and asthma, chest fullness and phlegm, and dry intestine constipation. Bitter almonds are rich in oil components, with a fat content of about 35% to 50%, of which linolenic acid and linoleic acid are the main components for treating dry intestine constipation. Bitter almonds can improve intestinal function by repairing part of the SCF / c-kit signaling pathway and promoting the expression of Cx43.
[0022] Beneficial Effects
[0023] The Chinese medicine composition provided by the present invention has a good laxative effect for deficiency constipation, and the prescription of polygonatum and angelica can play a synergistic effect on the total prescription. The Chinese medicine composition was gavaged into mice of the blood yin deficiency constipation model, and the time of the first black stool of the mice was significantly reduced, the number of feces particles, feces water content and carbon powder propulsion distance were significantly increased (P<0.05), serum motilin, P substance, vasoactive intestinal peptide were significantly increased, and gastrin was significantly reduced (P<0.001), indicating that constipation symptoms were significantly improved. The above results disclose that the laxative effect of the Chinese medicine composition provided by the present invention is significant. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Effect of the time of first black stool on the constipation model mice with blood-yin deficiency n=8)
[0025] Figure 2 Effects on the number of feces particles in 6 hours in mice with constipation caused by blood-yin deficiency n=8)
[0026] Figure 3 Effects of fecal water content on the blood-yin deficiency constipation model mice n=8)
[0027] Figure 4 Effect of charcoal powder on the propulsion distance of mice with blood-yin deficiency constipation model n=8)
[0028] Figure 5 Effects of MTL content in serum of mice with blood-yin deficiency and constipation n=8)
[0029] Figure 6Effects of Gas content in serum of mice with blood-yin deficiency and constipation model n=8)
[0030] Figure 7 Effects of serum SP content in mice with blood-yin deficiency and constipation n=8)
[0031] Figure 8 Effects of VIP content in serum of mice with blood-yin deficiency and constipation n=8)
[0032] Fig. 9 Effect of Angelica sinensis dosage on the time to first black stool in mice with blood-yin deficiency constipation model n=8)
[0033] Fig.10 Effect of Angelica sinensis dosage on the number of fecal particles in 6 hours in mice with blood-yin deficiency constipation model n=8)
[0034] Fig.11 Effect of Angelica sinensis dosage on fecal water content in mice with blood-yin deficiency constipation model n=8)
[0035] Fig.12 Effect of Angelica sinensis dosage on the carbon powder propulsion distance in mice with blood-yin deficiency constipation model (x±s, n=8)
[0036] Fig.13 Effect of Angelica sinensis dosage on serum MTL content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0037] Fig.14 Effect of Angelica sinensis dosage on serum Gas content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0038] Fig.15 Effect of Angelica sinensis dosage on serum SP content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0039] Fig.16 Effect of Angelica sinensis dosage on serum VIP content in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.17 Effect of Polygonatum odoratum dosage on the time to first black stool in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.18 Effect of Polygonatum odoratum dosage on the number of feces particles in 6 hours in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.19 Effect of Polygonatum odoratum dosage on fecal water content in mice with blood-yin deficiency constipation model (x±s, n=8) Fig. 20 Effect of Polygonatum sibiricum dosage on the charcoal powder propulsion distance in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.21Effect of Polygonatum odoratum dosage on serum MTL content in mice with blood-yin deficiency constipation model (x±s, n=8) Fig. 22 Effect of Polygonatum odoratum dosage on serum Gas content in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.23 Effect of Polygonatum odoratum dosage on serum SP content in mice with blood-yin deficiency constipation model (x±s, n=8) Fig.24 Effect of Polygonatum odoratum dosage on serum VIP content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0040] Fig.25 Effect of Huangjing (Rhizoma Polygonati Sinensis) on the time of first black stool in mice with constipation caused by deficiency of blood and yin (x±s, n=8)
[0041] Fig.26 Effect of Huangjing (Rhizoma Polygonati Sinensis) on the number of feces particles in 6 hours in mice with constipation caused by deficiency of blood yin (x±s, n=8)
[0042] Fig. 27 Effect of Polygonatum odoratum wine on fecal water content in mice with constipation caused by blood-yin deficiency (x±s, n=8)
[0043] Fig.28 Effect of Huangjing (Rhizoma Polygonati Sinensis) on the propulsion distance of charcoal powder in mice with constipation caused by deficiency of blood yin (x±s, n=8)
[0044] Fig.29 Effect of Huangjing (Rhizoma Polygonati Sinensis) on serum MTL content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0045] Fig.30 Effect of Polygonatum odoratum L. on serum Gas content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0046] Fig.31 Effect of Polygonatum odoratum on serum SP content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0047] Fig.32 Effect of Polygonatum odoratum on serum VIP content in mice with blood-yin deficiency constipation model (x±s, n=8)
[0048] (In Example 5, compared with the blank group: # P<0.05, ## P<0.01, ### P<0.001; compared with the model group: * P<0.05, ** P<0.01, *** P<0.001; compared with formula 2, △ P<0.05, △△ P<0.01, △△△ P<0.001; compared with formula 3, ▲P<0.05, ▲▲ P<0.01, ▲▲▲ P<0.001; compared with formula 4, ☆ P<0.05, ☆☆ P<0.01, ☆☆☆ P<0.001)
[0049] (Compared with the blank group in Examples 6 to 7: # P<0.05, ## P<0.01, ### P<0.001; compared with the model group: * P<0.05, ** P<0.01, *** P<0.001)
[0050] (In Example 8, compared with the blank group: # P<0.05, ## P<0.01, ### P<0.001; compared with the model group: * P<0.05, ** P<0.01, *** P<0.001; compared with formula 5, △ P<0.05, △△ P<0.01, △△△ P<0.001) Specific implementation plan
[0051] Example 1. Preparation of Chinese medicine composition
[0052] The steps are as follows: weigh the raw materials according to the weight of the following single prescription medicinal flavors:
[0053] (1) Formula 1: 9-15 parts of polygonatum, 6-12 parts of angelica, 6-10 parts of cistanche, 5-14 parts of hemp seed, 3-14 parts of citron, 5-10 parts of peach kernel, 6-10 parts of platycodon, and 5-10 parts of bitter almond.
[0054] (2) Formulation 2 (Polygonatum sibiricum + Angelica sinensis group): 10 parts of Cistanche deserticola, 10 parts of Cannabis sativa seeds, 10 parts of Citron, 6 parts of Peach kernel, 6 parts of Platycodon grandiflorum, and 6 parts of Bitter Apricot kernel.
[0055] (3) Formulation 3 (less Polygonatum group): 10 parts of Angelica sinensis, 10 parts of Cistanche deserticola, 10 parts of Cannabis sativa seeds, 10 parts of Citron, 6 parts of Peach Kernel, 6 parts of Platycodon grandiflorum, and 6 parts of Bitter Apricot Kernel.
[0056] (4) Formulation 4 (less angelica group): 10 parts of polygonatum, 10 parts of cistanche, 10 parts of hemp seeds, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0057] (5) Formula 5 (whole formula group): 10 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0058] (6) Formula 6: 10 parts of polygonatum, 3 parts of angelica, 10 parts of cistanche, 10 parts of hemp seeds, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0059] (7) Formulation 7: 10 parts of polygonatum, 6 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0060] (8) Formulation 8: 10 parts of polygonatum, 12 parts of angelica, 6 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0061] (9) Formula 9: 10 parts of polygonatum, 24 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0062] (10) Formulation 10: 6 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0063] (11) Formulation 11: 9 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0064] (12) Formulation 12: 15 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0065] (13) Formulation 13: 20 parts of polygonatum, 10 parts of angelica, 10 parts of cistanche, 10 parts of hemp seed, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon, and 6 parts of bitter almond.
[0066] (14) Formulation 14 (wine-cured polygonatum group): 10 parts of wine-cured polygonatum, 10 parts of angelica sinensis, 10 parts of cistanche deserticola, 10 parts of hemp seeds, 10 parts of citron, 6 parts of peach kernel, 6 parts of platycodon grandiflorum, and 6 parts of bitter almond.
[0067] Example 2. Preparation of a Chinese medicine composition, the steps are as follows:
[0068] (1) Weigh the raw materials according to the formula in Example 1.
[0069] (2) Grind into coarse powder, add appropriate amount of honey powder, and fill into a non-woven bag.
[0070] Example 3. Preparation of a Chinese medicine composition, the steps are as follows:
[0071] (1) Weigh the raw materials according to the formula in Example 1.
[0072] (2) Extract with water three times, add 8 times, 8 times, and 6 times the weight of the slices of medicine respectively, boil for 40 minutes each time, filter, and obtain the decoction, combine, and set aside.
[0073] (3) The decoction obtained in step (2) is concentrated under reduced pressure and dried in vacuum to obtain a dry extract, which is a solid Chinese medicine composition.
[0074] Example 4. Preparation of test samples
[0075] This example is a method for preparing the test sample in the intestinal moistening and laxative experiments in Examples 5, 6, 7, and 8, as follows: Step (1): weigh the raw materials of each weight fraction according to the formula in Example 1, Step (2): extract with water 3 times, add 8 times, 8 times, and 6 times the weight of the raw materials respectively, decoct for 40 minutes each time, filter, obtain a decoction, combine, and set aside. Step (3): concentrate the decoction obtained in step (2) under reduced pressure, vacuum dry, obtain a dry extract, and set aside. Step (4): dissolve the dry extract in a corresponding solvent to prepare a test solution before use.
[0076] A positive group was set up, and the positive drug was Runchang Pills. The test sample preparation method was as follows: the Runchang Pills were ground into powder and dissolved in a corresponding solvent to prepare a test solution.
[0077] The following efficacy test experimental groups are formulations 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 in Example 1, and the positive group, and the test solution is prepared according to Example 4.
[0078] Example 5. Effect of moistening intestines and relieving constipation in mice with blood-yin deficiency constipation model
[0079] 1. Instruments and Materials
[0080] 1.1 Instrument
[0081] Microplate reader (Tecan, Switzerland), Anke TGL-16B centrifuge (Anting Scientific Instrument Factory, Shanghai), BP211D electronic balance (Sartorius Scientific Instrument Co., Ltd.), KH-500DB CNC ultrasonic cleaner (Kunshan Hechuang Ultrasonic Instrument Co., Ltd.), intelligent digital display constant temperature electric heating jacket (Tongzhou Changtong Electric Heater Factory, Nantong City), DGG-9140A electric constant temperature blast drying oven (Shanghai Senxin Experimental Instrument Co., Ltd.), surgical scissors, surgical forceps, ruler, 1mL syringe.
[0082] 1.2 Reagents
[0083] Sodium carboxymethyl cellulose (AR, Sinopharm Chemical Reagent Co., Ltd., batch number 20190604), compound reserpine tablets (national medicine standard H32026532, Jiangsu Changjiang Pharmaceutical Co., Ltd., batch number 23090901), levothyroxine sodium tablets (national medicine standard J20160065, Merck Serono Co., Ltd., batch number C10012344), intestinal runner pills (national medicine standard Z20023314, Jiuzhitang Co., Ltd., batch number 202303047), activated carbon powder (Suzhou Carbon Cyclone Activated Carbon Co., Ltd., batch number Zk23231019005).
[0084] 1.3 Animals
[0085] SPF-grade ICR mice (weight 18-22 g) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., license number SYXK (Su) 2023-0077. The mice were kept in a comfortable and quiet environment with a room temperature of 20-24 °C and a relative humidity of 40-60%. The mice could drink water and eat freely without any other adverse factors.
[0086] 2. Animal Grouping
[0087] After one week of adaptive feeding, the mice were randomly divided into 7 groups: blank group, model group, positive group, and formula 2, 3, 4, and 5 groups, among which the positive group was Runchang Pills.
[0088] 3. Construction and drug administration of mouse model of blood-yin deficiency constipation
[0089] Except for the blank group, the mice in the other groups were given compound reserpine 0.3mg / kg and L-thyroxine 0.8mg / kg by gavage once a day for 7 consecutive days, and the tail vein was bled on the 1st, 3rd, 5th and 7th days. The tail was wiped with 75% alcohol to make the blood vessels congested, and the tail tip was cut off 0.1-0.2cm, and immersed in a 38℃ constant temperature water bath to make the mice bleed for 3min. The blank group was given an equal volume of 0.5% CMC-Na by gavage without bleeding.
[0090] After modeling, the mice were gavaged with an aqueous solution of the corresponding Chinese medicine composition (equivalent to the daily dosage for an adult weighing 60 kg) according to the scheme in Table 1, with a dosing volume of 10 mL / kg, once a day for 8 consecutive days.
[0091] Table 1 Dosage regimen for Example 5
[0092]
[0093] 4. Index determination
[0094] 4.1 Determination of time to first black stool, number of stool particles within 6 hours and stool water content
[0095] After the end of the drug administration on the 6th day, fasting but not water control was performed for 12 hours. 30 minutes after the drug administration on the 7th day, mice in each group were gavaged with 10% charcoal powder 0.1mL / 10g, and food and water were normal. The time of the first black stool excretion of the mice and the number of feces within 6 hours were recorded. The feces were collected for 6 hours, weighed the wet weight, dried in a constant temperature drying oven at 80℃ for 12 hours, weighed the dry weight, and the water content of the feces was calculated. Water content of feces = (wet weight-dry weight) / wet weight×100%.
[0096] 4.2 Determination of carbon powder advancement rate
[0097] On the 8th day, 30 minutes after drug administration, mice in each group were gavaged with 10% charcoal powder solution, 10 mL / kg. 30 minutes later, blood was collected from the eye sockets, and the mice were killed. The mesentery of the mice was separated, and the small intestine was taken out and straightened. The total length of the small intestine (the distance from the pylorus to the ileocecal part) and the distance of charcoal powder advancement (the distance from the pylorus to the front of the charcoal powder) were measured, and the charcoal powder advancement rate was calculated. Charcoal powder advancement rate = charcoal powder advancement distance / total length of small intestine × 100%.
[0098] 4.3 Determination of serum motilin (MTL), gastrin (Gas), substance P (SP) and vasoactive intestinal peptide (VIP)
[0099] After the whole blood of mice was allowed to stand at room temperature, it was centrifuged at 3000 rpm for 10 minutes to separate the serum, and the contents of MTL, Gas, SP, and VIP in the serum were determined according to the instructions of the corresponding ELSA kits. The methods and calculation formulas used for each index were strictly in accordance with the instructions of the kits.
[0100] Statistical analysis: GraphPad 8.0.2 (263) statistical software was used for data analysis. The comparison of means among multiple groups was carried out by one-way analysis of variance, and the statistical differences among groups were compared by T test. P < 0.05 was considered statistically significant.
[0101] 5. Experimental Results
[0102] 5.1 Time of first black stool, number of stool particles within 6 hours and stool water content
[0103] The slow transmission of colon contents caused by colonic motility disorder is one of the main causes of constipation. Slow colonic movement, increased time to the first black stool, and decreased stool quantity and water content are the main manifestations of changes in colonic motility in patients with constipation. By observing the time to the first black stool, the number of stool particles within 6 hours, the water content of stool, and the intestinal carbon propulsion rate of mice with blood-yin deficiency constipation, the effect of the formula on the intestinal motility of constipated mice and its laxative effect were determined.
[0104] (1) We measured the time of the first black stool in mice (see Figure 1), and found that compared with the blank group, the time to the first black stool of the mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the time to the first black stool of the mice in formula 2, 3, and 4 groups was reduced to varying degrees, and the time to the first black stool of the mice in the positive group and formula 5 group was significantly reduced (P<0.01, P<0.001); compared with formula 2, 3, and 4 groups, the time to the first black stool of the mice in formula 5 group was significantly different (P<0.05).
[0105] (2) We measured the number of fecal particles in mice within 6 h (see Figure 2 ), and found that compared with the blank group, the number of fecal pellets in the model group within 6 hours was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the number of fecal pellets in the mice in formula 2, 3, and 4 groups increased to varying degrees within 6 hours, and the number of fecal pellets in the mice in the positive group and formula 5 group increased significantly within 6 hours (P<0.001, P<0.01); compared with formula 2, 3, and 4 groups, the number of fecal pellets in the mice in formula 5 group within 6 hours showed significant differences (P<0.05).
[0106] (3) We measured the water content of mouse feces (see Figure 3 ), and found that compared with the blank group, the fecal water content of the mice in the model group was significantly reduced (P<0.01), indicating that the model was successfully established; compared with the model group, the fecal water content of the mice in formula 2 group was slightly increased, and the fecal water content of the mice in the positive group and the other formula groups was significantly increased (P<0.01); compared with formula 2, the fecal water content of the mice in formula 5 group was significantly increased (P<0.01).
[0107] 5.2 Carbon powder advancement rate
[0108] We measured the carbon propulsion rate of mice (see Figure 4 ), and found that compared with the blank group, the charcoal advancement rate of mice in the model group was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the charcoal advancement rate of mice in formula 2, 3, and 4 groups increased to varying degrees, and the charcoal advancement rate of mice in the positive group and formula 5 groups increased significantly (P<0.001); compared with formula 2, 3, and 4 groups, respectively, the charcoal advancement rate of mice in formula 5 group increased significantly (P<0.05).
[0109] 5.3 Motilin (MTL), gastrin (Gas), substance P (SP) and vasoactive intestinal peptide (VIP)
[0110] A variety of gastrointestinal hormones secreted by endocrine cells in the digestive tract are involved in the regulation of colonic motility, such as MTL and Gas. Abnormal expression of enteric neurotransmitters in the colon wall may be the main pathogenesis of constipation. When the enteric nervous system functions normally, neurotransmitters are in a balanced state, but when neurotransmitters lose coordination, it can lead to intestinal neuromuscular dysfunction, thereby affecting defecation. Therefore, this study determined the content of MTL, Gas, SP, and VIP in mouse serum to determine the effect of the formula on the intestines of constipated mice and its laxative effect.
[0111] (1) We measured the level of motilin in mouse serum (see Figure 5 ), and found that compared with the blank group, the level of motilin in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the level of MTL in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 2, 3, and 4 groups, respectively, the level of MTL in the serum of mice in formula 5 group was significantly increased (P<0.05).
[0112] (2) We measured gastrin in mouse serum (see Figure 6 ), and found that compared with the blank group, the gastrin content in the serum of the mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the Gas content in the serum of the mice in the positive group and each formula group was significantly decreased (P<0.001); compared with formula 2, 3, and 4 groups, respectively, the Gas content in the serum of the mice in formula 5 group was significantly decreased (P<0.001).
[0113] (3) We measured substance P in mouse serum (see Figure 7 ), it was found that compared with the blank group, the SP content in the serum of the mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the SP content in the serum of the mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 2, 3, and 4, respectively, the SP content in the serum of the mice in formula 5 group was significantly increased (P<0.05).
[0114] (4) We measured the vasoactive intestinal peptide in mouse serum (see Figure 8 ), and found that compared with the blank group, the VIP content in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the VIP content in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 2, 3, and 4 groups, respectively, the VIP content in the serum of mice in formula 5 group was significantly increased (P<0.001).
[0115] Example 6. Effect of Angelica sinensis dosage on bowel-moistening and laxative effects in mice with blood-yin deficiency constipation model
[0116] 1. Instruments and Materials
[0117] Same as Example 5
[0118] 2. Animal Grouping
[0119] After one week of adaptive feeding, the mice were randomly divided into 8 groups: blank group, model group, positive group, and formula 5, 6, 7, 8, and 9 groups, among which the positive group was Runchang Pills.
[0120] 3. Construction and drug administration of mouse model of blood-yin deficiency constipation
[0121] Same as Example 5, the dosage regimen is as follows:
[0122] Table 2 Dosage regimen for Example 6
[0123]
[0124] 4. Index determination
[0125] Same as Example 5
[0126] 5. Experimental Results
[0127] 5.1 Time of first black stool, number of stool particles within 6 hours and stool water content
[0128] (1) We measured the time of the first black stool in mice (see Fig. 9 ), and found that compared with the blank group, the time to the first black stool of mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the time to the first black stool of mice in formula 6 group was reduced, but there was no significant difference, and the time to the first black stool of mice in the positive group and other formula groups was significantly reduced (P<0.01); compared with formula 8, the time to the first black stool of mice in formula 9 group was not significantly reduced.
[0129] (2) We measured the number of fecal particles in mice within 6 hours (see Fig.10 ), and found that compared with the blank group, the number of fecal particles in the model group within 6 hours was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the number of fecal particles in the mice in formula 6 group increased within 6 hours, but there was no significant difference, and the number of fecal particles in the mice in the positive group and other formula groups within 6 hours was significantly increased (P<0.05); compared with formula 8, the number of fecal particles in the mice in formula 9 group within 6 hours did not increase significantly.
[0130] (3) We measured the water content of mouse feces (see Fig.11 ), and found that compared with the blank group, the feces water content of the mice in the model group was significantly reduced (P<0.05), indicating that the model was successfully established; compared with the model group, the feces water content of the mice in the positive group and each formula group was significantly increased (P<0.05); compared with formula 8, the feces water content of the mice in formula 9 group did not increase significantly.
[0131] 5.2 Carbon powder advancement rate
[0132] We measured the carbon propulsion rate of mice (see Fig.12 ), and found that compared with the blank group, the charcoal advancement rate of mice in the model group was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the charcoal advancement rate of mice in Formula 6 group increased, but there was no significant difference, and the charcoal advancement rate of mice in the positive group and other formula groups increased significantly (P<0.001); compared with Formula 8, the charcoal advancement rate of mice in Formula 9 group did not increase significantly.
[0133] 5.3 Motilin (MTL), gastrin (Gas), substance P (SP) and vasoactive intestinal peptide (VIP)
[0134] (1) We measured the level of motilin in mouse serum (see Fig.13 ), it was found that compared with the blank group, the content of motilin in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the content of MTL in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 8, the content of MTL in the serum of mice in formula 9 group did not increase significantly.
[0135] (2) We measured gastrin in mouse serum (see Fig.14 ), it was found that compared with the blank group, the gastrin content in the serum of the mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the Gas content in the serum of the mice in the positive group and each formula group was significantly decreased (P<0.001); compared with formula 8, the Gas content in the serum of the mice in formula 9 group did not decrease significantly.
[0136] (3) We measured substance P in mouse serum (see Fig.15 ), it was found that compared with the blank group, the SP content in the serum of the mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the SP content in the serum of the mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 8, the SP content in the serum of the mice in formula 9 group did not increase significantly.
[0137] (4) We measured the vasoactive intestinal peptide in mouse serum (see Fig.16 ), and found that compared with the blank group, the VIP content in the serum of mice in the model group was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the VIP content in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 8, the VIP content in the serum of mice in formula 9 group did not increase significantly.
[0138] Example 7. Effect of Polygonatum odoratum dosage on bowel-moistening and laxative effects in mice with blood-yin deficiency constipation model
[0139] 1. Instruments and Materials
[0140] Same as Example 5
[0141] 2. Animal Grouping
[0142] After one week of adaptive feeding, the mice were randomly divided into 8 groups: blank group, model group, positive group, and formula 5, 10, 11, 12, and 13 groups, among which the positive formula was Runchang Pills.
[0143] 4. Construction and drug administration of mouse model of blood-yin deficiency and constipation
[0144] Same as Example 5, the dosage regimen is as follows:
[0145] Table 3 Dosage regimen for Example 7
[0146]
[0147] 4. Index determination
[0148] Same as Example 5
[0149] 5. Experimental Results
[0150] 5.1 Time of first black stool, number of stool particles in 6 hours and water content of stool
[0151] (1) We measured the time of the first black stool in mice (see Fig.17 ), and found that compared with the blank group, the time to the first black stool of the mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the time to the first black stool of the mice in formula 10 group was reduced, but there was no significant difference, and the time to the first black stool of the mice in the positive group and other formula groups was significantly reduced (P<0.001); compared with formula 12, the time to the first black stool of the mice in formula 13 group was not significantly reduced.
[0152] (2) We measured the number of fecal particles in mice within 6 hours (see Fig.18 ), and found that compared with the blank group, the number of fecal pellets in the model group mice within 6 hours was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the number of fecal pellets in the formula 10 group mice within 6 hours increased, but there was no significant difference, and the number of fecal pellets in the positive group and other formula groups within 6 hours increased significantly (P<0.01); compared with formula 12, the number of fecal pellets in the formula 13 group mice within 6 hours did not increase significantly.
[0153] (3) We measured the water content of mouse feces (see Fig.19), and found that compared with the blank group, the fecal water content of the mice in the model group was significantly reduced (P<0.01), indicating that the model was successfully established; compared with the model group, the fecal water content of the mice in the positive group and each formula group was significantly increased (P<0.05); compared with formula 12, the fecal water content of the mice in formula 13 group did not increase significantly.
[0154] 5.2 Carbon powder advancement rate
[0155] We measured the carbon propulsion rate of mice (see Fig. 20 ), and found that compared with the blank group, the charcoal advancement rate of mice in the model group was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the charcoal advancement rate of mice in formula 10 group increased, but there was no significant difference, and the charcoal advancement rate of mice in the positive group and other formula groups increased significantly (P<0.001); compared with formula 12, the charcoal advancement rate of mice in formula 13 group did not increase significantly.
[0156] 5.3 Motilin (MTL), gastrin (Gas), substance P (SP) and vasoactive intestinal peptide (VIP)
[0157] (1) We measured the level of motilin in mouse serum (see Fig.21 ), it was found that compared with the blank group, the content of motilin in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the content of MTL in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 12, the content of MTL in the serum of mice in formula 13 group had no significant increase.
[0158] (2) We measured gastrin in mouse serum (see Fig. 22 ), it was found that compared with the blank group, the gastrin content in the serum of the mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the Gas content in the serum of the mice in the positive group and each formula group was significantly decreased (P<0.001); compared with formula 12, the Gas content in the serum of the mice in formula 13 group was not significantly reduced.
[0159] (3) We measured substance P in mouse serum (see Fig.23 ), it was found that compared with the blank group, the SP content in the serum of the mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the SP content in the serum of the mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 12, there was no significant increase in the SP content in the serum of the mice in formula 13 group.
[0160] (4) We measured the vasoactive intestinal peptide in mouse serum (see Fig.24), and found that compared with the blank group, the VIP content in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the VIP content in the serum of mice in the positive group and each formula group was significantly increased (P<0.001); compared with formula 12, the VIP content in the serum of mice in formula 13 group did not increase significantly.
[0161] Example 8. Effect of Polygonatum odoratum in wine on the bowel-moistening and laxative effect of mice with blood-yin deficiency constipation model
[0162] 1. Instruments and Materials
[0163] Same as Example 5
[0164] 2. Animal Grouping
[0165] After one week of adaptive feeding, the mice were randomly divided into 5 groups: blank group, model group, positive group, formula 5 and 14 groups, among which the positive group was Runchang Pills.
[0166] 5. Construction and drug administration of mouse model of blood-yin deficiency constipation
[0167] Same as Example 5, the dosage regimen is as follows:
[0168] Table 4 Dosage regimen for Example 8
[0169]
[0170] 4. Index determination
[0171] Same as Example 5
[0172] 5. Experimental Results
[0173] 5.1 Time of first black stool, number of stool particles in 6 hours and water content of stool
[0174] (1) We measured the time of the first black stool in mice (see Fig.25 ), and found that compared with the blank group, the time to the first black stool of mice in the model group was significantly increased (P<0.001), indicating that the model was successfully established; compared with the model group, the time to the first black stool of mice in the positive group, formula 5 group, and formula 14 group was significantly reduced (P<0.001); compared with formula 5, the time to the first black stool of mice in formula 14 group was significantly reduced (P<0.05).
[0175] (2) We measured the number of fecal particles in mice within 6 hours (see Fig.26 ), and found that compared with the blank group, the number of fecal pellets in the model group within 6 hours was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the number of fecal pellets in the positive group, formulation 5 group, and formulation 14 group within 6 hours was significantly increased (P<0.001); compared with formulation 5, the number of fecal pellets in the formulation 14 group within 6 hours was significantly increased (P<0.01).
[0176] (3) We measured the water content of mouse feces (see Fig. 27 ), and found that compared with the blank group, the feces water content of the mice in the model group was significantly reduced (P<0.001), indicating that the model was successful; compared with the model group, the feces water content of the mice in the positive group was significantly increased (P<0.01), and the feces water content of the mice in the formula 5 group and the formula 14 group was significantly increased (P<0.001); compared with the formula 5, the feces water content of the mice in the formula 14 group was significantly increased (P<0.05).
[0177] 5.2 Carbon powder advancement rate
[0178] We measured the carbon propulsion rate of mice (see Fig.28 ), and found that compared with the blank group, the charcoal advancement rate of mice in the model group was significantly reduced (P<0.001), indicating that the model was successfully established; compared with the model group, the charcoal advancement rate of mice in the positive group, formula 5 group, and formula 14 group was significantly increased (P<0.001); compared with formula 5, the charcoal advancement rate of mice in formula 14 group was significantly increased (P<0.05).
[0179] 5.3 Motilin (MTL), gastrin (Gas), substance P (SP) and vasoactive intestinal peptide (VIP)
[0180] (1) We measured the level of motilin in mouse serum (see Fig.29 ), and found that compared with the blank group, the content of motilin in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the content of MTL in the serum of mice in the positive group, formula 5 group, and formula 14 group was significantly increased (P<0.001); compared with formula 5, the content of MTL in the serum of mice in formula 14 group was significantly increased (P<0.05).
[0181] (2) We measured gastrin in mouse serum (see Fig.30 ), and found that compared with the blank group, the gastrin content in the serum of the mice in the model group was significantly increased (P<0.001), indicating that the model was successful; compared with the model group, the Gas content in the serum of the mice in the positive group, formula 5 group, and formula 14 group was significantly decreased (P<0.001); compared with formula 5, the Gas content in the serum of the mice in formula 14 group was significantly decreased (P<0.01).
[0182] (3) We measured substance P in mouse serum (see Fig.31), it was found that compared with the blank group, the SP content in the serum of the mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the SP content in the serum of the mice in the positive group, formula 5 group, and formula 14 group was significantly increased (P<0.001); compared with formula 5, the SP content in the serum of the mice in formula 14 group was significantly increased (P<0.05).
[0183] (4) We measured the vasoactive intestinal peptide in mouse serum (see Fig.32 ), and found that compared with the blank group, the VIP content in the serum of mice in the model group was significantly decreased (P<0.001), indicating that the model was successfully established; compared with the model group, the VIP content in the serum of mice in the positive group, formulation 5 group, and formulation 14 group was significantly increased (P<0.001); compared with formulation 5, the VIP content in the serum of mice in formulation 14 group was significantly increased (P<0.01).
Claims
1. A Chinese medicine composition for moistening the intestine and relieving constipation, characterized in that The invention comprises the following raw materials in parts by weight: 9 to 15 parts of polygonatum sibiricum and 6 to 12 parts of angelica sinensis.
2. The Chinese medicine composition according to claim 1, characterized in that: 10 parts of polygonatum and 10 parts of angelica.
3. The Chinese medicine composition according to claim 1, characterized in that The invention comprises the following raw materials in parts by weight: 9-15 parts of polygonatum, 6-12 parts of angelica, 6-10 parts of cistanche, 5-14 parts of hemp seeds, 3-14 parts of bergamot, 5-10 parts of peach kernel, 6-10 parts of platycodon and 5-10 parts of bitter almond.
4. The Chinese medicine composition according to claim 3, characterized in that: 10 parts of polygonatum, 10 parts of angelica, 10 parts of cistanches, 10 parts of cannabis seeds, 10 parts of citrons, 6 parts of peach kernels, 6 parts of platycodon grandiflorum, and 6 parts of bitter almonds.
5. The Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The polygonatum sibiricum is wine polygonatum sibiricum.
6. Use of the Chinese medicine composition according to any one of claims 1 to 5 in the preparation of foods, health foods and medicines with laxative functions.
Citation Information
Patent Citations
Medicament for treating constipation and preparation method thereof
CN103169863A
